Cholinesterase inhibitors — donepezil, rivastigmine, galantamine — are FDA-approved for Alzheimer's disease and have additional indications (donepezil for severe AD, rivastigmine for Parkinson's disease dementia). The off-label use in other cognitive conditions has accumulated some evidence base, with selective clinical applications. The longevity-psychiatry frame engages these agents in defined scenarios beyond pure dementia indications — Lewy body dementia, vascular cognitive impairment, possibly cognitive deficits in schizophrenia — with realistic expectations about modest effect sizes.
Lewy body dementia is a strong off-AD indication. Rivastigmine has the best evidence in DLB and Parkinson's disease dementia; cholinergic deficits in DLB are often more severe than in Alzheimer's disease, and the response to cholinesterase inhibition can be substantial. The clinical use is established despite the FDA approval being specifically for AD; the off-label use is supported by trial evidence and clinical experience. The dosing is similar to AD use.
Vascular cognitive impairment has moderate evidence. Donepezil and galantamine have shown some benefit in vascular dementia trials, with smaller effect sizes than in AD but clinically meaningful in selected patients. The mechanism rationale is mixed — cholinergic deficits in VCI are variable — but the clinical practice includes consideration for VCI patients with adequate evidence of cholinergic responsiveness.
Schizophrenia cognitive deficits have explored cholinergic targeting. The persistent cognitive deficits in schizophrenia (working memory, processing speed, executive function) have been a treatment target with limited success. Cholinesterase inhibitors and direct nicotinic agonists have been investigated; the evidence is limited and routine clinical use is uncommon. The persistent gap in effective schizophrenia cognitive treatment remains.
The clinical considerations and limitations. Side effects (GI symptoms, vivid dreams, bradycardia, syncope risk in older patients, weight loss) limit tolerability. Effect sizes are modest even in approved indications. The risk-benefit calculation in off-label use requires patient-by-patient assessment. The decision typically involves: clear cognitive symptoms warranting intervention, exclusion of alternatives, adequate informed consent about off-label use and modest expected benefit, time-limited trial with assessment of effect. The discipline is to use cholinesterase inhibitors where they have meaningful evidence (AD, DLB, PD dementia, selected VCI cases), recognize their off-label use in other indications as requiring case-by-case justification, and integrate with broader treatment that addresses cognitive symptoms through multiple pathways.